Sodium polystyrene sulfonate

PreclinicalSmall molecule

Sodium polystyrene sulfonate is one of 5 small molecule programs targeting Hyperkalemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperkalemiaActive, not recruiting

HyperkalemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Hyperkalemia

#DrugCompanyPhaseTrials

Salbutamol

GSK

Phase 3

2 2

Insulin 320

Novo Nordisk

Phase 3

1 3

Veltassa

VVifor Pharma

Phase 3

7 4

WS016

WWaterstone Pharmaceutical (Wuhan) Co., LTD.

Phase 3

2 5

Sodium polystyrene sulfonate

ZZS Pharma, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hyperkalemia2 trials

Safety and Efficacy of Sodium Polystyrene Sulfonate in Hyperkalemia

Terminated·ZZS Pharma, Inc.·Phase 4·NCT01866709·32 enrolled

SZC Versus SPS for Treatment of Hyperkalemia in Hemodialysis Patients

Completed·—·N/A·NCT06029179·120 enrolled

Dialysis Patients1 trial

Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Pre-dialysis Patients

Completed·MMaisonneuve-Rosemont Hospital·Phase 4·NCT02065076·38 enrolled

MPA1 trial

Comparison of Potassium Binders in the ER

Terminated·UUniversity of California, Irvine·Phase 4·NCT04585542·37 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Sodium polystyrene sulfonate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sodium polystyrene sulfonate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sodium polystyrene sulfonate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ZS Pharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: ZZS Pharma, Inc.

Sodium polystyrene sulfonate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hyperkalemia2 trials

Dialysis Patients1 trial

MPA1 trial

References

Drug Info

Quick Facts

Related News